logo
Latin America Must Pay More Attention to Zero-Dose Children

Latin America Must Pay More Attention to Zero-Dose Children

Medscape11-06-2025
The United Nations Children's Fund has reported that approximately 2.7 million children younger than 1 year in Latin America have incomplete vaccination schedules. Even more concerning is the high number of 'zero-dose' children — those who have never been taken to a vaccination center at all. Due to the risks this population faces, experts from the Latin American Society of Pediatric Infectious Diseases are calling for increased regional attention in an article published in the journal F1000Research .
'This article is relevant because discussions around vaccination often focus solely on coverage, which may appear high, while overlooking a significant proportion of children who haven't received a single vaccine. This creates a serious risk for them, which is why it's essential to identify and prioritize them for vaccination,' said María Ávila Agüero, MD, pediatric infectious disease specialist, article author, former Minister of Health of Costa Rica, and current head of Infectious Diseases at Carlos Sáenz Herrera National Children's Hospital in San José, Costa Rica.
Operationally, zero-dose children are defined as those who have never received even a first dose of a vaccine containing diphtheria, tetanus, and pertussis components. The article includes a series of recommendations for improving outreach to this population, based on discussions from a symposium organized by the medical society in late 2023 in Costa Rica.
Latin America lacks precise data on zero-dose populations, though between 2021 and 2022, the Americas saw a 14% reduction in their number — from 1.85 million to 1.31 million. Globally, Mexico and Brazil were among the 20 countries with the highest number of zero-dose children during that period.
In 2023, regional coverage for the first dose of the diphtheria, tetanus, and pertussis vaccine reached 89%. However, there are wide disparities between countries: From 65% in Venezuela to 99% in the Dominican Republic, Chile, Cuba, Costa Rica, and others.
COVID Disrupted Vaccine Programs
'The COVID-19 pandemic changed everything, as resources were redirected to control it, which affected other programs — including vaccination and health education,' Ávila Agüero noted. 'Although recovery is underway, it's uneven and depends heavily on the strength of each country's health ministry and public policies.'
Aurora Bautista Márquez, MD, a pediatrician with extensive public health experience and former head of the Comprehensive Child Development Division at the Mexican Social Security Institute, who did not contribute to the article, commented: 'This article is both interesting and important because it reminds us of a persistent and concerning issue in the region.'
'There is a constant risk of the reemergence or outbreak of vaccine-preventable diseases,' she emphasized.
She also agreed that the pandemic significantly affected vaccination coverage: 'At the start of the pandemic, basic vaccination coverage among children under 5 dropped sharply, as many parents avoided taking their children to health centers for fear of SARS-CoV-2 infection.' With the rollout of COVID vaccines, attendance at vaccination centers improved, and so did coverage rates.
'I find the data in this article very helpful, as they allow us to understand the scale of the problem in each country,' added Bautista Márquez.
How to Reach Zero-Dose Children
The article stressed the importance of identifying and characterizing the issue in each country. Understanding who the zero-dose children are, where they live, and why they haven't been reached is essential. With these insights, countries can tailor approaches and implement effective, sustainable interventions.
In some areas, vaccine supply shortages complicate efforts. In others, access is hindered by distrust, poverty, low socioeconomic status, discrimination, or religious beliefs.
To address the problem, the authors prioritized the need for better nominal electronic vaccination records across the region. These digital tools allow for tracking vaccine data, optimizing supply distribution, and facilitating the rollout of timely, effective strategies.
Bautista Márquez agreed: 'In my opinion, the most cost-effective strategy is undoubtedly the creation of nominal systems to accurately track the vaccination status of children.'
Another major point raised was the need to strengthen communication about the benefits of vaccination. Public trust in vaccines — damaged during the COVID pandemic — is a key factor in acceptance. To rebuild that trust, the article calls for evidence-based information campaigns involving community leaders, religious groups, healthcare providers, and other stakeholders.
'Involvement of healthcare workers in shaping public perception of vaccination and education about vaccines play a major role and can help prevent vaccine hesitancy,' the study authors wrote.
On this point, Ávila Agüero urged Latin American physicians not to miss any opportunity to vaccinate. She emphasized the importance of reviewing vaccination cards, approaching families with empathy and respect, addressing concerns, and not minimizing fears. Bautista Márquez added that healthcare professionals must also be well-informed about vaccine contraindications, as a lack of knowledge can lead to many missed opportunities.
Political Will Is Essential
Tackling inequities and ensuring that vaccination programs are equitable and reach all children — regardless of socioeconomic status, ethnicity, or geography — is a pressing task for policymakers in the region.
Vaccines must be readily available and accessible to all children, including those in remote or underserved areas and among migrant populations. The article highlights solutions such as mobile vaccination units, extended clinic hours, and outreach programs that target marginalized communities.
Bautista Márquez noted that while many of the strategies discussed are already being implemented, basic issues — like untimely vaccine supply — have resulted in many children in Mexico being unvaccinated or incompletely vaccinated. 'We shouldn't wait for outbreaks of vaccine-preventable diseases. That's unacceptable. Measures must be taken to prevent vaccine shortages. Investment is also needed in training and information systems to better track childhood immunization schedules across the region,' she said.
Ávila Agüero underscored the importance of political will in Latin America to mobilize resources and ensure equitable access to vaccination services. 'The article expresses concern but also support for the region's health ministries. It issues a call to action at a time of heightened epidemiological risk,' she concluded.
All authors, along with Bautista Márquez and Ávila Agüero, declared having no relevant financial conflicts of interest.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nelipak starts construction on new healthcare packaging plant in Costa Rica
Nelipak starts construction on new healthcare packaging plant in Costa Rica

Yahoo

time2 days ago

  • Yahoo

Nelipak starts construction on new healthcare packaging plant in Costa Rica

Healthcare packaging solutions provider Nelipak has initiated construction of a new facility in Costa Rica's Green Valley, Grecia, Alajuela. The 60,000ft² industrial facility is being developed in partnership with Costa Rican real-estate developer Portafolio Inmobiliario. The facility, which is expected to open in mid-2026, will substantially increase Nelipak's capacity and capabilities in the region. It will expand production capabilities to include thin- and heavy-gauge thermoforming, die-cut pouch cards, and inserts. The site will boast International Organization for Standardization (ISO) 13485 certification and include ISO-7 clean room manufacturing space, adhering to the highest standards for sterile-barrier healthcare packaging. Nelipak CEO Pat Chambliss expressed excitement about the construction commencement, emphasising the company's dedication to its South American and Caribbean customers. "This investment underscores our long-term commitment to our customers in Latin America and the Caribbean, and reflects our strategy to provide global excellence with strong local support," said Chambliss. Costa Rica Minister of Foreign Trade Manuel Tovar lauded Nelipak's expansion as a testament to the company's confidence in Costa Rica as a strategic platform for its specialised packaging solutions in the life sciences packaging sector. "We congratulate Nelipak for its commitment to innovation, the creation of quality employment, and the promotion of sustainable growth for the benefit of our country and the region," Tovar remarked. Since acquiring ATE in 2012, Nelipak has been operating in Costa Rica, supplying medical device manufacturers with custom packaging products. The new facility will provide additional warehousing and distribution space, allowing for future growth in line with customer demands. Nelipak said the new plant reinforces Costa Rica's status as a prime location for medical device manufacturing and underscores its role as a key player in the global healthcare supply chain. Nelipak employs 1,400 people across 11 sites globally, comprising six sites in North America and five sites in Europe. Earlier this year, Nelipak said it would invest in the future of sterile-barrier medical packaging in the Asia-Pacific egion, with an intention to extend its capabilities to meet increasing customer requirements. "Nelipak starts construction on new healthcare packaging plant in Costa Rica" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Nelipak® Breaks Ground on New Healthcare Packaging Facility in Grecia, Alajuela Costa Rica
Nelipak® Breaks Ground on New Healthcare Packaging Facility in Grecia, Alajuela Costa Rica

Yahoo

time5 days ago

  • Yahoo

Nelipak® Breaks Ground on New Healthcare Packaging Facility in Grecia, Alajuela Costa Rica

CRANSTON, R.I., July 25, 2025 (GLOBE NEWSWIRE) -- Nelipak® Corporation ('Nelipak®'), a leading global provider of healthcare packaging solutions for medical device, diagnostic, pharmaceutical drug delivery, and other demanding applications, announced that it has officially broken ground on its new, state-of-the-art production facility in Costa Rica Green Valley in Grecia, Alajuela. The groundbreaking ceremony marks a major milestone in Nelipak's continued investment in Costa Rica and its commitment to supporting the growing medical device manufacturing ecosystem in the region. Slated to open in mid-2026, the 60,000 square-foot Class-A industrial facility will significantly expand Nelipak's regional capacity and capabilities. The new site will be ISO 13485 certified and include ISO-7 cleanroom manufacturing space designed to meet the highest standards of quality and safety for sterile-barrier healthcare packaging. 'We are thrilled to celebrate the start of construction on our newest facility in Costa Rica,' said Pat Chambliss, CEO of Nelipak. 'This investment underscores our long-term commitment to our customers in Latin America and the Caribbean, and reflects our strategy to provide global excellence with strong local support.' The facility is being built in collaboration with Portafolio Inmobiliario, a leading real estate developer in Costa Rica, and is tailored to Nelipak's operational and sustainability requirements. 'We are pleased to welcome this multinational company to the Costa Rica Green Valley project. The beginning of its construction marks an important step in consolidating our project as an ideal ecosystem for leading global companies. We are proud to be part of Nelipak's growth in Costa Rica and to continue driving projects that combine innovation, sustainability, and world-class development,' said Alfredo Volio, Executive Director of Portafolio Inmobiliario. 'We enthusiastically celebrate Nelipak's new investment and the inauguration of its modern production center in Grecia. This expansion reaffirms the company's confidence in Costa Rica as a strategic platform for its specialized packaging solutions in the life sciences sector. With this investment, the value chain of key sectors such as medical devices and the pharmaceutical industry is strengthened, consolidating Costa Rica as a reliable partner for the production of high-value solutions. We congratulate Nelipak for its commitment to innovation, the creation of quality employment, and the promotion of sustainable growth for the benefit of our country and the region,' stated Manuel Tovar, Minister of Foreign Trade. 'The expansion of Nelipak in Costa Rica contributes to strengthening our value chain and consolidating the country as a hub for the manufacturing of medical devices and other high value-added industries. According to the latest Free Trade Zone Report, local purchases in the country reached US$5.621 billion, which demonstrates how these investments boost our exports while energizing Costa Rica's productive ecosystem. The growth of companies like Nelipak reinforces this synergy and confirms Costa Rica's appeal for strategic sectors that demand quality, reliability, and innovation,' said Laura López, CEO of the Trade and Investment Promotion Agency of Costa Rica (PROCOMER). Nelipak has operated in Costa Rica since its acquisition of ATE in 2012, serving leading medical device manufacturers with thermoformed trays, die-cut mounting cards, and other custom packaging products. The new facility will broaden production capabilities to include thin- and heavy-gauge thermoforming, die-cut pouch cards, and inserts. It will also offer enhanced warehousing and distribution space for Nelipak's flexible packaging product lines and allow for future expansion as customer needs evolve. This groundbreaking further positions Costa Rica as a premier hub for medical device manufacturing and reinforces Nelipak's role as a trusted packaging partner in the global healthcare supply chain. About Nelipak® Nelipak® is a leading global provider of healthcare packaging solutions including rigid and flexible sterile-barrier packaging for medical device, diagnostic, pharmaceutical drug delivery, and other demanding applications. To support the development of innovative sustainable packaging solutions, Nelipak® offers in-house design, prototyping, tooling, simulation, validation, laboratory, and other value-added services as well as a line of tray sealing equipment. With 1,400 employees and 11 sites globally, including 6 sites in North America (US, Costa Rica, Puerto Rico) and 5 sites in Europe (Ireland, Netherlands, UK), Nelipak® is committed to delivering superior quality, service, and customer experience through world-class cleanroom manufacturing. For more information, visit Follow us on: LinkedIn: Twitter: CONTACT: Nelipak® Marketing Contact: Seán Egan Director of Global Marketing Nelipak® +353-91-709-163 Press Contact: Jordan Bouclin SVM Public Relations 401-490-9700 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

This Brazilian Startup Is Turning A Population Of 211 Million Into A Cannabis Data Goldmine
This Brazilian Startup Is Turning A Population Of 211 Million Into A Cannabis Data Goldmine

Forbes

time03-07-2025

  • Forbes

This Brazilian Startup Is Turning A Population Of 211 Million Into A Cannabis Data Goldmine

Toninho Corrêa While much of the world watches Germany and the U.S. inch forward on cannabis reform, Brazil has quietly become home to a fast-growing and highly structured medical cannabis market. And helping drive that transformation is a mobile app (not a clinic, cultivator or multinational) that's redefining patient access in one of the world's most complex regulatory environments. It's called Blis, and if you haven't heard of it yet, you're not alone. Built entirely in Brazil by a team of local developers and patients, the platform has already reached more than 300,000 users, generates R$2 million (about $363,000) in monthly revenue and holds what may be the largest real-world cannabis patient database in Latin America. With a population of more than 211 million, Brazil is Latin America's largest potential market for medical cannabis, but also one of the most complex to navigate. Under ANVISA's RDC 660 and RDC 327, cannabis prescriptions are legal, but only for imported, pharmaceutical-grade products, and only with doctor supervision. Despite those constraints, analysts project Brazil's medical cannabis sector could exceed $4.4 billion by 2032, driven by rising demand, decreasing stigma and a worsening mental health crisis. Across the region, Latin America's legal cannabis market is expected to reach $3.75 billion by 2028, with Brazil accounting for a significant share, especially if CBD flower is reauthorized for import in the coming months, opening an entirely new vertical for digital platforms. Born From Patients, Built For Brazil Blis didn't begin in a boardroom; it started with a group of Brazilian patients, frustrated by the painful logistics of getting medical cannabis legally. 'We faced enormous difficulties,' said CEO Toninho Corrêa. 'From the medical consultation to the import bureaucracy.' The existing system was slow, scattered and intimidating. So they built something new: an app approved by both Apple and Google that allows full legal access to cannabis treatment in Brazil, from doctor consultation to home delivery, in just a few taps. According to Corrêa, the platform has reduced access time by 160x, collapsing what used to take weeks into a seamless digital experience. And as cannabis adoption in Brazil shifts from critical conditions like Parkinson's and epilepsy toward broader wellness use (for sleep, anxiety, stress and focus), demand is accelerating. 'In practice, we are creating an entirely new market in Brazil for this type of alternative therapy,' he said. Rather than adapt a foreign model, Blis was built locally from the ground up, with Brazilian regulations, payment systems and patient behavior in mind. 'Importing a foreign model wouldn't work,' Corrêa said. 'We needed a solution tailored to the country's regulatory and cultural context.' That local-first approach has now positioned Blis as a scalable model for the rest of Latin America — and beyond. Numbers That Speak For Themselves In under a year, Blis has surpassed 300,000 downloads and now reaches patients in more than 1,800 cities and towns across Brazil, including many rural areas where medical support is limited or nonexistent. According to the company, over 60% of users who complete a consultation go on to purchase a product. Furthermore, the platform boasts a 42% repurchase rate, signaling strong adherence to treatment plans. Blis App The average order value is around R$1,000 (roughly $182) and the top-selling products are gummies and oils focused on sleep, anxiety and focus, an indicator of Brazil's shifting relationship with cannabis: less taboo, more therapeutic. 'Gummies grew faster than we expected,' Corrêa said, noting their popularity among women aged 30 to 45, who favor discreet, precisely dosed formats. Adoption is also rising among patients over 60, especially for sleep support and chronic pain relief; a demographic often overlooked in global cannabis marketing. 'We're not just seeing growth in the typical early adopter audience. This is mainstream,' he added. A Massive Cannabis Patient Dataset You've Probably Never Heard Of Beyond product sales, Blis is quietly building something even more valuable: data. With over 25,000 real-world patient records and growing, the platform now manages what it claims is one of the largest clinical cannabis databases in Latin America, a resource that could shape treatment standards, support clinical trials and inform regulatory strategy across the region. The company says all data collection follows strict LGPD standards and informed consent protocols. The top three conditions being treated on the platform are insomnia, anxiety and stress, a mental health trifecta that has surged across Brazil in the wake of COVID-19 and ongoing economic instability. Corrêa says the company is now exploring partnerships with researchers and institutions to translate this data into high-impact clinical insights. 'This is a living ecosystem. We're just getting started.' Blis says it handles patient data in full compliance with Brazil's General Data Protection Law (LGPD), using anonymization protocols for any internal studies or aggregated analysis. 'Only authorized professionals have access to patient records, with full traceability and consent controls,' Corrêa noted. While no personal data is currently shared with third parties, Blis may partner with research institutions in the future — but only under strict ethical review and legal safeguards. 'Patients are always informed about how their data is used and can revoke consent at any time,' Corrêa said. Corrêa also noted a sharp rise in interest for gummies, particularly among women and older patients, who value simplicity, discretion and routine. 'We were surprised by how fast that segment matured,' he said. It's a signal that, when designed well, medical cannabis can meet people where they are, without intimidation or stigma. A Market Shaped By Regulation — But Led By Patients From the outside, Brazil's medical cannabis landscape can look impenetrable. But insiders like Corrêa argue that perception no longer matches reality. 'Many still think cannabis is illegal or only accessible in very severe cases,' he said. 'But ANVISA's RDCs 660 and 327 allow legal access with a prescription. The real issue isn't regulation; it's public awareness and access.' In that gap, Blis has positioned itself as both a healthcare facilitator and an information bridge. The company has invested heavily in educational outreach, working with media outlets, conservative audiences and even older patient groups to dispel misconceptions and normalize treatment. 'We made a point of starting Blis' communication through more traditional channels,' Corrêa said. 'That helped us build credibility in places where cannabis was still taboo.' A potential turning point looms: the reauthorization of CBD flower imports, which ANVISA is reportedly considering in the coming weeks. If approved, it would open a new therapeutic category for platforms like Blis, allowing faster-acting, inhalable options for patients with chronic pain, advanced conditions or prior experience with cannabis. 'We're ready,' Corrêa said. 'This would expand our product portfolio and create new experiences for patients who need different kinds of relief.' From Patient App To Platform Play Blis may have started as a fix for a broken access system, but it's now eyeing a far larger opportunity. The company says it hit breakeven within six months, now counts over 25,000 active patients and projects a valuation of over $100 million by year's end, up from roughly $60 million today. The roadmap ahead includes expanding to at least one Latin American market by 2025, launching new technology and service channels, and publishing the company's first clinical data report based on its growing patient base. 'We're building toward a R$1 billion valuation by 2027,' Corrêa said, 'but more importantly, we're building trust.' To reach that next phase, Blis is currently in conversations with investors, strategic partners and scientific collaborators — both in Brazil and internationally. Corrêa says he's open to capital, but only when it aligns with the company's mission. 'What we're looking for is more than money. It's regulatory expertise, clinical insight and the ability to scale responsibly.' Latin America Is Watching Although Blis was built specifically for Brazil's regulatory maze, its model, combining technology, medical guidance and legally compliant distribution, could travel well. 'Blis was built to scale,' Corrêa said. 'Countries like Colombia, Argentina and Mexico are already advancing cannabis regulations, and we see a strong fit for digital platforms that educate and reduce stigma.' Each country brings its own challenges, but the demand patterns — anxiety, insomnia, chronic pain — are strikingly similar across Latin America. Corrêa believes Brazil's unique mix of tight regulations and huge unmet demand has forced innovation in a way that could serve as a template for emerging markets. 'Brazil may lag in public perception, but we lead in digital access,' he said. Compared to countries like Colombia, which has prioritized cultivation, or Mexico, where legal ambiguity continues to stall implementation, Brazil's patient-first approach, anchored in ANVISA oversight and doctor supervision, may prove more scalable in the long term. And while most of the international cannabis spotlight remains focused on North America and Europe, Corrêa is confident: 'The next wave of cannabis innovation may not come from where people expect.' Redefining Wellness, One Click At A Time For Corrêa, cannabis is just the beginning. 'Blis is not just a cannabis company: it's a new model of wellness for Latin America,' he said. The platform's long-term vision includes expanding into personalized protocols, new therapeutic categories, and broader public health integration, all grounded in real-world data and patient experience. As mental health needs grow and healthcare systems strain under demand, platforms like Blis are positioning themselves not just as dispensers of product, but as scalable infrastructure for care. 'The debate is no longer led by regulators,' Corrêa said. 'It's led by patients.' Blis may not have brand recognition in North America — yet — but its trajectory offers a glimpse of what cannabis innovation can look like when it's rooted in need, built with purpose, and shaped by the realities of the people it serves.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store